ALLR Allarity Therapeutics, Inc.

Overview and Growth

Allarity Therapeutics, Inc. generated $320.00K of revenue in fiscal 2025, with net loss of $11.23M and an operating cash outflow of $14.82M. The $320.00K revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. At period end, total assets were $18.26M, framing the scale of the company’s operating and financing commitments. Asset turnover was 0.02x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

Operations produced a $12.61M operating loss before non-operating and tax effects. After all below-operating-line items, the company recorded a net loss of $11.23M for the fiscal year. Before income taxes, the company recorded a loss of $11.23M, bridging the operating result to the final net loss. The reported income-tax provision was $0.00, the amount recognized between pretax income and the final net-income result. The loss-to-equity relationship was 114.3%, placing the bottom-line deficit against shareholder capital. The loss-to-assets relationship was 61.5%, placing the bottom-line deficit against the company’s resource base. Compared with a $24.52M net loss in fiscal 2024, the current loss improved to $11.23M.

Liquidity and Capital Structure

At period end, the $18.26M asset base was financed through $8.43M of liabilities and $9.83M of equity. Current assets were $17.93M against $8.43M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 2.13x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Cash and equivalents totaled $14.69M, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 174.2%, excluding receivables and other current assets. The equity-to-assets relationship was 53.8%, placing book capital against the total resource base. Relative to total assets, liabilities measured 46.2%, complementing the separate equity-based view of the company’s capital structure. Cash and equivalents equaled 80.4% of total assets, showing the liquid cash component within the company’s broader resource base. Total assets were 19.4% lower than fiscal 2024 assets of $22.65M, measuring the company’s own balance-sheet change. Book equity was 16.8% lower than fiscal 2024 equity of $11.81M, showing how shareholder capital changed year over year. Cash and equivalents were 24.8% lower than fiscal 2024 cash of $19.53M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $14.82M, showing that operations absorbed cash during the period. Capital expenditures used $8.00K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. The company recorded a $14.83M cash deficit after capital spending for the period. Relative to total assets, the post-investment cash deficit measured 81.2%. Cash absorbed by operations decreased from $17.35M in fiscal 2024 to $14.82M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.